Coherus Biosciences announced it received FDA approval for Udenyca OnBody® the on-body injector presentation of Udenyca® (pegfilgrastim-cbqv), biosimilar to Amgen’s Neulasta®. Udenyca® is administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. Commercial availability is planned for Q1 2024.
Coherus resubmitted its Biologics License Application (BLA) supplement for Udenyca OnBody® to the FDA in October 2023, following a satisfactory resolution of inspection findings at a third-party filler. The resubmission comes after addressing the sole issue identified in the FDA’s Complete Response Letter it received on 21 September 2023.